What You Should Know:
– Eko Health, a leader in AI-powered early detection of heart and lung diseases, announced today a successful Series D financing round of $41 million.
– This funding, led by ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, will fuel Eko’s mission to expand access to its innovative platform in the U.S. and globally.
Building on a Strong Foundation of Innovation and Clinical Validation
This funding round comes on the heels of significant commercial and clinical achievements for Eko. Their AI algorithms for detecting structural heart murmurs and low ejection fraction (Low EF) have both received FDA clearance in the US.
- Structural Heart Murmur Detection: A Massachusetts General Hospital study demonstrated Eko’s algorithm to be twice as effective as conventional practices in primary care for identifying structural heart murmurs.
- Low Ejection Fraction Detection: Developed in collaboration with Mayo Clinic, Eko’s algorithm was shown in an Imperial College London study to significantly improve the identification of heart failure with reduced ejection fraction in general practitioner clinics.
By enhancing detection capabilities, Eko’s platform streamlines diagnosis, facilitating earlier interventions and improving patient outcomes.
Addressing the Global Burden of Cardiovascular and Pulmonary Disease
Cardiovascular and pulmonary diseases are leading causes of death worldwide. Millions remain undiagnosed due to limited access to effective detection tools. Eko bridges this gap by integrating sophisticated AI capabilities into routine physical exams. This ranges from primary care settings like NCH Healthcare System in the US to maternal-fetal health exams in Nigeria.
Global Expansion and Empowering Healthcare Professionals
Eko will leverage the new capital to solidify its US presence and accelerate international expansion. This is further bolstered by strategic investments from Double Point Ventures (US), EDBI (Singapore’s economic development board’s investment arm), and LG Technology Ventures (backed by LG Group of South Korea).
With this funding, regulatory clearances, and a growing network of global partners, Eko is poised to rapidly expand access to its AI-powered platform. This will empower millions of healthcare professionals to improve patient outcomes in the coming years.
"Eko harnesses AI to unlock universal access to expert-level cardiac and pulmonary disease detection for patients everywhere,” said Connor Landgraf, CEO and co-founder of Eko Health. “Just as Ring transformed doorbells into home security systems, Eko has reinvented the world’s most ubiquitous medical tool into a powerful early disease detection platform, creating the world’s largest install base of professional AI-enabled cardiology devices."
